Raj Persaud

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

Retrieved on: 
Monday, January 9, 2023

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D).

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D).
  • Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia.
  • “We are excited to announce Doug’s appointment,” said Steve Davis, Acadia’s Chief Executive Officer.
  • Dr. Williamson brings more than 20 years of research, development, and commercial experience to his new role.

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Retrieved on: 
Wednesday, September 7, 2022

VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment of Doug Williamson to the Company’s Board of Directors (the “Board”). Dr. Williamson will serve on the Compensation, Nominating and Corporate Governance, and Audit Committees as an independent director. Concurrently, Dr. Alan Kozikowski has resigned from the Board.

Key Points: 
  • Dr. Williamson will serve on the Compensation, Nominating and Corporate Governance, and Audit Committees as an independent director.
  • Dr. Williamson has an impressive track record in developing safe and profitable pharmaceuticals and biotechnologies for global industry leaders.
  • With his reputation for generating quality results while improving ROI and building high-performance, engaged teams, we are thrilled to welcome Dr. Williamson to the Board, stated Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.
  • BMB-101 is the subject of a patent licensed by Bright Minds Biosciences from the University of Illinois.

Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer

Retrieved on: 
Monday, February 14, 2022

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer.

Key Points: 
  • DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer.
  • Doug is an outstanding addition to the Avadel leadership team given his extensive experience in the biopharmaceutical industry leading R&D, clinical development and medical affairs teams in the neuroscience field, said Greg Divis, Chief Executive Officer of Avadel.
  • Dr. Williamson has more than 25 years of scientific, clinical and medical experience primarily focused on neuroscience.
  • He joins Avadel from Lundbeck, where he served as Senior Vice President, Head of U.S. R&D and Deputy Global Chief Medical Officer.